Levocetirizine

Introduction Overview

Generic Name

levocetirizine

Brand Name

Xyzal, Levrix

Dosage Form

oral solution (2.5 mg/5 mL), oral tablet (5 mg)

Drug Class

Antihistamines

Pharmacokinetics

Absorption:
Levocetirizine is rapidly and well absorbed following oral administration, with peak plasma concentrations typically achieved within approximately 0.9 hours. The drug demonstrates high oral bioavailability, exceeding 90%, which ensures effective systemic exposure after administration. Food intake has minimal impact on the extent of absorption but may slightly delay the time to peak concentration. Pediatric patients tend to absorb levocetirizine twice as much as adults at equivalent doses, which necessitates careful dosing in children to avoid increased systemic exposure and potential toxicity.

Distribution:
Levocetirizine exhibits a volume of distribution of approximately 0.4 L/kg, indicating limited tissue penetration beyond the extracellular fluid. The drug is minimally bound to plasma proteins, with plasma protein binding ranging from 90% to 95%, primarily to albumin. This moderate to high plasma protein binding affects drug interactions minimally. The drug crosses the placental barrier in minimal amounts but is excreted into breast milk, leading to recommendations against breastfeeding during therapy. Due to its properties, penetration into the central nervous system is limited, correlating with a low incidence of sedative effects compared to first-generation antihistamines.

Metabolism:
Levocetirizine undergoes negligible hepatic metabolism, being primarily eliminated in unchanged form. The metabolic transformation of levocetirizine is minimal, rendering the drug less susceptible to cytochrome P450 enzyme interactions. This metabolic profile offers a favorable interaction profile with concomitant medications. In vitro and clinical studies indicate insignificant involvement of hepatic enzymes, which accounts for a reduced risk of hepatic drug interactions.

Elimination:
The primary route of elimination for levocetirizine is renal excretion, with approximately 85% of the administered dose excreted unchanged in urine. The elimination half-life ranges between 7 to 10 hours in adults, facilitating once-daily dosing regimens. Renal clearance is influenced by kidney function; impaired renal clearance necessitates dose adjustment or avoidance in severe renal disease or patients on dialysis. The drug's clearance is not significantly altered in hepatic impairment due to minimal metabolism, but clearance reductions in renal disease require clinical consideration. The drug's elimination kinetics support steady plasma concentrations with once-daily dosing, contributing to effective symptom control in allergic conditions.

Dosage Forms

Available Dosage Forms:
Levocetirizine is commercially available in two primary oral dosage forms:
- Oral tablet: 5 mg tablets intended for once-daily administration.
- Oral solution: 2.5 mg/5 mL liquid formulation, beneficial for pediatric patients and those with swallowing difficulties.

Dosages for Adults and Adolescents:
- For chronic urticaria in adults, the standard dose is 5 mg orally once daily in the evening; some patients demonstrate adequate symptom control with 2.5 mg once daily.
- For seasonal allergic rhinitis (available OTC), adults and adolescents aged 12 years and older are typically prescribed 5 mg orally once daily in the evening, with some requiring only 2.5 mg daily.

Specific Patient Populations:
- Pediatric Patients: The dosing varies by age group due to different pharmacokinetic handling and tolerability.
* 6 months to 2 years: 1.25 mg orally once daily in the evening (dose should not be exceeded).
* 6 to 11 years: 2.5 mg orally once daily in the evening for seasonal allergic rhinitis; 2.5 mg once daily also for urticaria.
* 12 years and older: 5 mg orally once daily; some patients may require only 2.5 mg.
- Renal Impairment: Levocetirizine is contraindicated in patients with end-stage renal disease or those receiving dialysis. Dose adjustments are necessary for moderate renal impairment to prevent drug accumulation and adverse effects.
- Hepatic Impairment: No dose adjustment is necessary since levocetirizine undergoes minimal hepatic metabolism.

Clinical Guidelines:
Levocetirizine is typically administered once daily in the evening, with or without food. Accurate dosing in pediatric patients is vital due to increased absorption relative to adults. The liquid formulation allows precise dosing with the use of a provided syringe or medicine measuring device. Clinical response and tolerability should be monitored, and dose adjustments made accordingly, especially in special populations such as children and patients with renal dysfunction.

Mechanism Of Action

Levocetirizine is a potent and selective antagonist of peripheral H1 receptors, which mediate the effects of histamine released during allergic reactions. Histamine, a biogenic amine, binds to H1 receptors on various cells, including endothelial cells, smooth muscle cells, and sensory nerves, triggering symptoms such as vasodilation, increased vascular permeability, itching, and bronchoconstriction. By competitively inhibiting histamine binding at these receptors, levocetirizine prevents the cascade of inflammatory events that result in classic allergic symptoms.

At the cellular level, levocetirizine inhibits the activation of signaling pathways associated with histamine-mediated responses, such as phospholipase C activation, leading to reduced intracellular calcium mobilization and decreased release of pro-inflammatory mediators. This molecular inhibition results in the attenuation of capillary permeability and sensory nerve stimulation that produce itchiness and swelling in allergic conditions.

Unlike first-generation antihistamines, levocetirizine's chemical structure allows it to minimally cross the blood-brain barrier, reducing central nervous system penetration and thus decreasing sedative side effects. It selectively targets peripheral H1 receptors without notable affinity for muscarinic or alpha-adrenergic receptors, minimizing anticholinergic or cardiovascular side effects.

Clinical studies have demonstrated that levocetirizine effectively reduces symptoms in allergic rhinitis and chronic idiopathic urticaria by diminishing histamine-induced inflammatory responses. Its high receptor affinity, prolonged receptor binding, and favorable pharmacologic profile contribute to sustained symptom control with once-daily dosing. Comparative studies show levocetirizine to have similar or superior efficacy and better tolerability than older antihistamines, supporting its use as a first-line agent in allergic disease management.

Pharmacological Actions

Selective peripheral H1 receptor antagonism to counteract histamine action in allergic reactions.
Inhibition of histamine-induced vasodilation and increased vascular permeability.
Reduction of pruritus and urticarial wheal formation by blocking sensory nerve activation.
Minimal penetration of the blood-brain barrier leading to low sedation potential.
Negligible anticholinergic activity, minimizing common side effects such as dry mouth and urinary retention.
Prolonged receptor occupancy allowing once-daily dosing with sustained symptom relief.
Anti-inflammatory activity through indirect attenuation of histamine-mediated cytokine release.
Reduction of nasal congestion, rhinorrhea, sneezing, and ocular symptoms in allergic rhinitis.
Symptom relief in chronic idiopathic urticaria by suppressing histamine-induced mast cell degranulation effects.
Low potential for drug-drug interactions due to minimal hepatic metabolism.

Therapeutic Or Clinical Uses

Management of seasonal allergic rhinitis (hay fever) symptoms including sneezing, runny nose, itchy or watery eyes.
Treatment of perennial (year-round) allergic rhinitis.
Relief of symptoms in chronic idiopathic urticaria, such as itching and hives.
Symptomatic treatment of allergic reactions to insect bites and stings.
Use in adults and children aged 6 months and older for allergy symptom control.
Selected as an over-the-counter option for allergy symptom relief in appropriate patient populations.
Adjunct therapy for allergic conditions where avoidance of histamine release is impractical.
Alternative treatment in patients intolerant or unresponsive to other second-generation antihistamines.
Useful in patients requiring once-daily dosing and minimal sedation risk.
Employed to improve quality of life in patients with chronic allergy-associated discomfort.

Side Or Adverse Effects

Common adverse effects include drowsiness and fatigue, though less frequent than with first-generation antihistamines.
Sinus pain and ear infections have been reported during therapy.
Gastrointestinal disturbances such as vomiting, diarrhea, and constipation may occur.
Dry mouth is noted in some patients, albeit rarely.
Occasional episodes of nosebleeds have been observed.
Some reports of weight gain have been associated with chronic use.
Serious allergic reactions to levocetirizine are rare but can include hives, swelling, and difficulty breathing.
Severe itching on discontinuation after long-term use has been reported in rare cases.
Urinary retention or difficulty urinating may occur, particularly in predisposed individuals.
Potential for sedation is increased if combined with alcohol or other CNS depressants.
Occasional light-headedness or dizziness may be experienced.
Fever and ear-related symptoms indicative of infection warrant medical evaluation.
Elderly and renal-impaired patients may exhibit increased sensitivity to side effects.
Rare neurological effects such as headache or nervousness may occur.
Hypersensitivity reactions including rash and swelling are possible.

Precautions

Use cautiously in patients with moderate to severe renal impairment; dosing adjustments necessary.
Avoid use in children younger than 6 months of age.
Not recommended for use in patients with end-stage renal disease or on dialysis.
Exercise caution in patients with liver disease, although levocetirizine is minimally metabolized hepatically.
Monitor patients with a history of prostatic hypertrophy or urinary retention for urinary difficulties.
Avoid concurrent use with other CNS depressants or alcohol to minimize additive sedation.
Discontinue and contact healthcare provider if severe itching develops after long-term use.
Pregnant patients should consult healthcare providers; levocetirizine is not expected to harm the fetus, but benefits must outweigh risks.
Breastfeeding is not recommended due to excretion into breast milk.
Measure oral liquid doses accurately with proper syringes or measuring devices to avoid overdose.
Avoid exceeding recommended doses as increased dosing does not improve efficacy and raises risk of adverse effects.
Patients should disclose all medications to healthcare providers to prevent drug interactions.
Inform patients about potential sedation and advise caution when driving or operating machinery until response to medication is known.
Instruct patients to report signs of fever or ear infection promptly.
Evaluate for potential drug interactions in polypharmacy situations, especially with drugs causing CNS depression.

Warnings

Severe itching upon discontinuation after prolonged daily use has been rarely reported; medical consultation is required in such events.
Contraindicated in patients with known hypersensitivity to levocetirizine or cetirizine.
Not to be used in children under 6 months due to lack of safety data.
Avoid in patients with end-stage kidney disease or those on dialysis due to risk of drug accumulation.
Potential for sedation exists; caution advised when performing tasks requiring alertness until individual response is known.
Concomitant use with CNS depressants including opioids, benzodiazepines, muscle relaxants, and anxiety medications may potentiate drowsiness.
Overdose may lead to severe drowsiness; emergency care should be sought immediately.
Use during pregnancy only if clearly needed and prescribed by a healthcare provider.
Breastfeeding mothers should avoid levocetirizine due to drug passage into milk.
Patients should not exceed prescribed dosing; self-medication with higher doses increases risk of adverse effects without additional benefit.
Monitor for urinary retention, particularly in patients with predisposing conditions.
Allergic reactions to levocetirizine or related compounds necessitate immediate discontinuation and medical attention.
In patients with a history of multiple drug allergies, cautious initiation is advised.
Long-term use safety profile is supported, but close monitoring for adverse effects is recommended.

Contraindication

Hypersensitivity to levocetirizine or cetirizine hydrochloride.
End-stage renal disease patients, particularly those undergoing dialysis.
Children younger than 6 months of age.
Known allergy to any components of the levocetirizine formulation.
History of severe allergic reactions to any second-generation antihistamines.
Patients with significant urinary retention or obstruction without medical supervision.
Avoid use in patients with severe hepatic impairment only if prescribed, due to limited data.
Concomitant use with drugs that may cause additive central nervous system depression should be careful and monitored.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should avoid liquid formulation containing lactose.

Drug Interactions

Concurrent administration with CNS depressants such as opioids, benzodiazepines, muscle relaxants, and certain anti-anxiety medications may increase sedation.
Co-administration with ritonavir, a protease inhibitor, may alter levocetirizine pharmacokinetics and requires cautious use.
Theophylline may interfere with the metabolism or clearance of levocetirizine, necessitating dosage monitoring.
Avoid combination with alcohol due to enhanced central nervous system depressant effects.
Minimal interaction potential with cytochrome P450 substrates due to negligible hepatic metabolism.
Use with other antihistamines can potentiate anticholinergic side effects and is generally not recommended.
Caution is advised when used with medications that impair renal function, as levocetirizine elimination is renal.
No significant interaction reported with common over-the-counter medications, but patient monitoring is advised.
Potential pharmacodynamic interactions with muscle relaxants leading to enhanced sedation.
Drugs that modify gastric pH do not significantly affect levocetirizine absorption.
Interactions with herbal supplements and vitamins are not well documented; caution and consultation recommended.
Patients should inform their healthcare providers of all concomitant medications to avoid unforeseen interactions.
Multiple drug interaction studies show levocetirizine has a relatively safe profile but vigilance is advised in polypharmacy.
No clinically relevant interactions identified with commonly co-administered antihypertensives.

Preparations Of The Drug

Levocetirizine oral tablets available at 5 mg strength intended for once-daily intake.
Levocetirizine oral solution concentration of 2.5 mg per 5 mL, designed for accurate pediatric dosing.
Brand formulations under the trade names Xyzal and formerly Levrix (discontinued).
Both prescription and over-the-counter preparations are available, with OTC marketed mainly for allergy symptom control.
Formulations tailored for ease of administration in pediatric patients and those with swallowing difficulties.
Dosing devices such as oral syringes included with liquid formulations to ensure accurate measurement.
Packaging designed to protect from moisture and heat; storage at room temperature recommended.
Non-coated and coated tablet formulations for enhanced palatability and patient compliance.
Compliance packaging available including blister packs to improve adherence in chronic therapy.
Generic options widely available offering cost-effective alternatives to branded products.
Various strength preparations used internationally with similar dosing regimens adhering to guidelines.
Preparations formulated without alcohol or sugar to improve tolerability.
Liquid formulations suitable for infants and toddlers starting from 6 months of age under medical supervision.
Some preparations include excipients like lactose; patients with intolerance should consult healthcare providers.
Stability data support shelf life of 2-3 years when stored under recommended conditions.